Get the Daily Brief
Latest Biotech News
Boehringer discovers cGAS inhibitors: new candidates for interferon-driven diseases
Boehringer Ingelheim reported discovery of small-molecule cGAS inhibitors with potential applications across autoinflammatory interferonopathies, idiopathic pulmonary fibrosis,...
Targeting cell-death pathways: Cathepsin L and sibiriline offer dual benefits for cancer and degeneration
Two independent preclinical advances map therapeutic routes through regulated cell-death pathways. A Nature Communications study identified Cathepsin L as a dual target that suppresses tumor...
Kedrion wins EU orphan designation for aceruloplasminemia: plasma-derived therapy advances
Kedrion SpA announced European Medicines Agency orphan-drug designation for its investigational plasma-derived therapy to treat congenital aceruloplasminemia. The designation aims to facilitate...
Single 2‑ml mirikizumab injection bioequivalent to two 1‑ml doses: administration simplified
A clinical pharmacology study led by Otani, Payne and Loftus showed a single 2‑ml subcutaneous injection of mirikizumab is bioequivalent to two separate 1‑ml injections in healthy volunteers. The...
Biotech funding lifelines: investors press maturity, seek alternative financing
Industry leaders at an LSX Investival panel urged biotechs to raise scientific maturity and clinical validation before seeking large investment rounds. Speakers from Blackstone, Limerston Capital...
FDA’s plausible‑mechanism pathway: proposal to speed bespoke rare‑disease approvals
The FDA and authors including CBER director Vinay Prasad and Martin Makary published a ‘‘plausible mechanism’’ pathway in the New England Journal of Medicine proposing a streamlined route to...
mRNA boosts off‑the‑shelf MSC therapy: DC‑25 emerges
Researchers reported engineering allogeneic mesenchymal stem cells (MSCs) with mRNA to enhance immunomodulatory properties and created a candidate called DC‑25 that aims to overcome limitations of...
Off‑the‑shelf mRNA cancer vaccines: new candidates target liver tumors
A team published preclinical data on off‑the‑shelf mRNA vaccines designed to target hepatocellular carcinoma (HCC), reporting antigen selection and immune responses supportive of further...
VT‑3989 halts NF2‑deficient tumor growth: Vivace posts preclinical efficacy
Vivace Therapeutics disclosed preclinical efficacy for VT‑3989, a TEAD inhibitor that suppressed growth of NF2‑deficient meningioma models in vitro and in vivo. Company data show tumor growth...
M‑3554 ADC shows activity in soft‑tissue sarcoma models – developer reports
Preclinical results for M‑3554, an antibody‑drug conjugate (ADC) targeting GD2 with a β‑glucuronide linker and exatecan payload, demonstrate potent antitumor activity in neuroblastoma and...
Kymera patents STAT6 inhibitors: new small‑molecule program disclosed
Kymera Therapeutics filed patents disclosing STAT6 inhibitors as small‑molecule therapeutics with indications spanning cancer, inflammatory and metabolic diseases. The disclosure outlines chemical...
Boehringer unveils cGAS inhibitors: candidates for fibrotic and autoimmune disease
Boehringer Ingelheim disclosed discovery of cGAS inhibitors aimed at autoinflammatory interferonopathies, pulmonary fibrosis, MASH, systemic sclerosis and lupus. The disclosure describes chemical...
Eli Lilly files RXFP1 agonists: relaxin‑receptor program surfaces
Eli Lilly published chemical series of RXFP1 (relaxin receptor 1) agonists mapped to potential indications including pulmonary hypertension, kidney disease and diabetic nephropathy. The disclosure...
Telix shareholders urged to contact Robbins LLP: TLX class action notice
A legal notice from Robbins LLP announced a proposed class action related to Telix Pharmaceuticals (NASDAQ: TLX), advising shareholders with significant losses during the specified class period to...
Biotech funding lifelines: investors counsel strategies to cross ‘valley of death’
Industry panellists at the LSX Investival Showcase Europe outlined practical strategies for biotechs to navigate the funding ‘‘valley of death’’ between seed rounds and commercialization. Speakers...
Kedrion wins EMA orphan tag — aceruloplasminemia plasma therapy
Kedrion SpA secured European orphan drug designation from the EMA for its investigational plasma-derived treatment for congenital aceruloplasminemia. The designation advances Kedrion’s program...
VT-3989 shows preclinical potency — Vivace targets NF2-deficient tumors
Vivace Therapeutics reported preclinical efficacy for VT-3989, a TEAD inhibitor, in in vitro and in vivo models of aggressive NF2‑deficient tumors including meningioma. Company data show tumor...
M-3554 ADC shows strong activity: soft-tissue sarcoma models
Researchers disclosed robust antitumor activity for M‑3554, an antibody–drug conjugate (ADC) targeting GD2 that uses a β‑glucuronide linker and an exatecan payload, in neuroblastoma and...
Fimecs, Astellas expand pact — two new targets added
Raqualia Pharma’s Fimecs subsidiary and Astellas Pharma expanded their 2022 joint research collaboration by adding two new targets focused on targeted protein degradation. The agreement extends an...
Boehringer reveals cGAS inhibitors — pipeline for interferonopathies
Boehringer Ingelheim disclosed discovery of novel cyclic GMP‑AMP synthase (cGAS) inhibitors argued to be useful across a spectrum of inflammatory and fibrotic indications, from autoinflammatory...